Predict your next investment

TriLink BioTechnologies company logo
HEALTHCARE | Biotechnology
trilinkbiotech.com

See what CB Insights has to offer

Stage

Acq - Fin | Alive

About TriLink BioTechnologies

TriLink manufactures oligonucleotides, modified nucleoside triphosphates, mRNA and long RNA.

TriLink BioTechnologies Headquarter Location

9955 Mesa Rim Road

San Diego, California, 92121,

United States

800-863-6801

Latest TriLink BioTechnologies News

Korean companies eyeing mRNA vaccines to treat cancer

Aug 17, 2021

Korean companies eyeing mRNA vaccines to treat cancer 바로가기 기자명 Kim Chan-hyuk 닫기 Korean companies are actively studying how to use mRNA technology not only to fight Covid-19 but to treat cancer. In other countries, researchers are conducting clinical trials of a combination of mRNA vaccine and immunotherapy. Moderna teamed up with Merck, and CureVac/BioN Tech with Roche/Genetech, to test the combo therapy in solid cancer. In Korea, Theragen Bio, ST Pharm, and Celltrion have announced either a plan for cooperation for mRNA technology or an introduction to an mRNA technology platform to develop a next-generation cancer vaccine. Korean companies are working on mRNA vaccines to treat cancer. ST Pharm and Theragen Bio said on Tuesday that they have signed a memorandum of understanding (MOU) to jointly study a “neo-antigen mRNA anticancer vaccine” and cooperation in CDMO (contract development manufacturing organization) business. In developing an mRNA vaccine for cancer, researchers predict antigens by analyzing major mutations and characteristics of cancer cells’ genes extracted from cancer patients and administering mRNA that produces the antigens to induce an immune response that specifically responds to cancer cells. Under the MOU, ST Pharm will provide the 5 Prime-Capping and lipid nanoparticle (LNP) transfer platform technology for Theragen Bio and manufacture mRNA-LNP vaccine solutions from clinical trials to post-commercialization. Theragen Bio will derive mRNA anticancer vaccine candidates using the neo-antigen prediction method through artificial intelligence (AI)-based gene sequencing. ST Pharm, working on an mRNA vaccine against Covid-19, is also developing a vaccine to treat cancer. Celltrion said it signed an agreement with TriLink BioTechnologies of the U.S. on Aug. 4 to develop a next-generation mRNA vaccine platform. Located in San Diego in the U.S., TriLink is a CDMO based on an mRNA platform, having the vector and third-generation capping technology CleanCap, essentially required for mRNA vaccine development. TriLink will verify antigen sequence and utilize its capping technology to produce materials for Celltrion’s phase 1 and phase 2 trials. It will also provide Celltrion with template vector and mRNA processing technology that enables GMP production. Utilizing this, Celltrion will develop next-generation vaccines against Covid-19 and its variants and work on an mRNA platform using Celltrion’s patented technology simultaneously, the company said. By developing an mRNA platform, Celltrion will expand the mRNA technology from Covid-19 treatment to other diseases, including cancer, it added. “The mRNA technology has drawn attention since the outbreak of Covid-19, but companies are trying to develop a cancer vaccine. In addition, Moderna is expanding mRNA technology to influenza vaccines,” an industry source said. “The market using mRNA technology will keep growing.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

TriLink BioTechnologies Patents

TriLink BioTechnologies has filed 10 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/20/2016

2/9/2021

Molecular biology, Biotechnology, RNA, Genetics, Gene delivery

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/20/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, RNA, Genetics, Gene delivery

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

TriLink BioTechnologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TriLink BioTechnologies Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.